HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma

Cancer Research

Volumn 61, Issue 20, 2001, Pages 7642-7646

  Polsky, David ^a   Hazan, Carole ^a   Melzer, Kate ^a   Osman, Iman ^a   Pack, Jason ^b   Houghton, Alan ^b   Busam, Klaus ^b   Cordon Cardo, Carlos ^b   Bastian, Boris C ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN MDM2; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DYSPLASTIC NEVUS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; SOUTHERN BLOTTING; WESTERN BLOTTING;

CELL TRANSFORMATION, NEOPLASTIC; COHORT STUDIES; DYSPLASTIC NEVUS SYNDROME; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0035887146     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Molecular genetics of familial cutaneous melanoma
2. Mutation and expression of the p53 gene in human malignant melanoma
3. Molecular biology of melanoma
4. Mdm2: Keeping p53 under control
5. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line
6. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis
7. The MDM2 gene amplification database
8. Expression of mdm-2 oncoprotein in the primary and metastatic sites of mammary tumor (GI-101) implanted athymic nude mice
9. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis
10. Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/C1P1
11. MDM2 oncogene as a target for cancer therapy: An antisense approach
12. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
13. Classification and staging
14. Tissue microarrays for high-throughput molecular profiling of tumor specimens
15. Detection of 20q13 gain by dual-color FISH in breast cancers
16. Gene amplification in human cancers: Biological and clinical significance
17. Mapping of the p53 and mdm-2 interaction domains
18. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
19. Altered patterns of MDM2 and TP53 expression in human bladder cancer
20. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer
21. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
22. Inactivation of p53-pathway in squamous cell carcinoma of the head and neck: Impact on treatment outcome in patients treated with larynx preservation intent
23. Amplification of a gene encoding a p53-associated protein in human sarcomas
24. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors
25. Validation of tissue microarray technology in breast carcinoma
26. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization
27. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin
28. Mutational analysis of the human p53 gene in malignant melanoma
29. Overexpression of MDM-2 is a frequent and early event in melanoma development
30. 1/S checkpoint regulators in metastatic melanoma
31. Prognostic value of biomarkers in malignant melanoma
32. p53 and mdm-2 expression in malignant melanoma: An immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors
33. Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression
34. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs)
35. MDM2 overexpression with alteration of the p53 protein and gene status in oral carcinogenesis
36. MDM2/p53 protein expression in the development of colorectal adenocarcinoma
37. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells
38. Abnormal expression of MDM-2 in breast carcinomas
39. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein
40. Induction of Mdm2 and enhancement of cell survival by bFGF
41. Opposing effects of Ras on p53: Transcriptional activation of mdm2 and induction of p19ARF
42. Growth factors and melanomas
43. Prognostic factors for survival of patients treated systemically for disseminated melanoma
44. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas
45. Role of oncogenes in resistance and killing by cancer therapeutic agents